Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update

Sino Biopharmaceutical (OTCMKTS:SBMFF) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 26,678,100 shares, a decrease of 28.3% from the May 15th total of 37,216,500 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is currently 38,111.6 days. Approximately 0.1% of the shares of the stock are short sold.

Sino Biopharmaceutical Stock Down 0.6%

Shares of SBMFF stock opened at $0.64 on Thursday. The stock has a 50 day simple moving average of $0.53 and a 200-day simple moving average of $0.45. Sino Biopharmaceutical has a 1-year low of $0.31 and a 1-year high of $0.77.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.